MARKET

TARA

TARA

Protara Therapeutics Inc
NASDAQ
4.600
-0.500
-9.80%
Pre Market: 4.900 +0.3 +6.52% 05:19 05/19 EDT
OPEN
5.10
PREV CLOSE
5.10
HIGH
5.16
LOW
4.490
VOLUME
10
TURNOVER
0
52 WEEK HIGH
7.82
52 WEEK LOW
2.770
MARKET CAP
258.54M
P/E (TTM)
-3.4021
1D
5D
1M
3M
1Y
5Y
1D
Protara Therapeutics To Host Investor Webinar On TARA-002 Program And Treatment Landscape For Lymphatic Malformations On May 19, 2026
Benzinga · 22h ago
Protara Therapeutics to host virtual investor webinar on TARA-002 for lymphatic malformations
PUBT · 22h ago
Weekly Report: what happened at TARA last week (0511-0515)?
Weekly Report · 1d ago
Protara Therapeutics Reports 55% Complete Response Rate In Bladder Cancer Study
Benzinga · 3d ago
Unusually active option classes on open May 15th
TipRanks · 3d ago
Protara announces updated 12-month data from Cohort A of ADVANCED-2 trial
TipRanks · 3d ago
Protara Reports Positive Phase 2 Data For TARA-002 In Bladder Cancer Study
NASDAQ · 3d ago
Protara Therapeutics Reports TARA-002 Achieves 72% Complete Response Rate In BCG-Naïve NMIBC Patients With Durable 55% Rate At 12 Months
Benzinga · 3d ago
More
About TARA
Protara Therapeutics, Inc. is a clinical-stage biotechnology company focused on advancing transformative therapies for people with cancer and rare diseases. The Company's portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin, as well as a Phase II trial in pediatric patients with LMs. TARA-002 is a first-in-class TLR2/NOD2 agonist and novel immunopotentiator derived from inactivated Streptococcus pyogenes. Additionally, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral support who are otherwise unable to meet their choline needs via oral or enteral routes.

Webull offers Protara Therapeutics Inc stock information, including NASDAQ: TARA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TARA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TARA stock methods without spending real money on the virtual paper trading platform.